Medical and practical eligibility for long-acting cabotegravir/rilpivirine in adolescents and young adults living with HIV in tertiary care clinic

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20240608002

Enrollment

100

Registered

2024-06-08

Start date

2024-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To identify proportion of adolescents who are medical eligible as well as attitudes towards long-acting cabotegravir/rilpivirine Long-acting antiretroviral therapy, HIV, cabotegravir, rilpivirine, attitude, adolescents, young adult, acceptability

Interventions

Patients living with HIV who aware of their status with ongoing follow up at buddy CU clinic, Chulalongkorn university

Health Services Research

Youth living with HIV in buddy CU clinic

Eligibility

Sex/Gender

All

Age

13 Years to 24 Years

Inclusion criteria

Inclusion criteria: Adolescents and young adults aged 13-24 years old living with HIV Aware of their HIV status

Exclusion criteria

Exclusion criteria: Ever has injectable anti-retroviral drug(s) for treatment or prevention.

Design outcomes

Primary

Measure	Time frame
Number of eligible patients At patient visit after time of enrollment Number	—

Secondary

Measure	Time frame
attitude of adolescent living with HIV regarding the use long-acting injectable ART. At patient visit after time of enrollment Likert scale	—

Countries

Thailand

Contacts

Public ContactPunnathorn Auabonkanok

Faculty of Medicine, Chulalongkorn University

punnathorn.au@gmail.com0807268565

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026